Coronary disease & ACSGuideline or statement
Antithrombotic therapy after coronary artery bypass graft surgery: a Clinical Consensus Statement of the ESC Working Group on Cardiovascular Surgery, the ESC Working Group on Cardiovascular Pharmacotherapy, and the European Association for Cardio-Thoracic Surgery (EACTS)
- Clinical consensus statement
Recommendations
As issued by the authors
Antithrombotic therapy is essential after CABG to reduce ischaemic events and prevent graft occlusion
In higher-risk patients, DAPT or antiplatelet therapy combined with OAC may be beneficial, but increases bleeding risk
Choice of antithrombotic therapy tailored to each patient's ischaemic and bleeding risks and regularly reassessed
Original publication
Antithrombotic therapy after coronary artery bypass graft surgery: a Clinical Consensus Statement of the ESC Working Group on Cardiovascular Surgery, the ESC Working Group on Cardiovascular Pharmacotherapy, and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. Published 30 August 2025. doi:10.1093/eurheartj/ehaf423
Summarised from the published abstract; every number is checked against it